# KPV: Research Overview — Peptide Testimonials > A literature summary of KPV, the anti-inflammatory tripeptide derived from alpha-MSH, studied only in cell culture and animal colitis models. Covers mechanism, cited animal findings, and why no human trial or meaningful user-report record exists. An anti-inflammatory tripeptide derived from alpha-MSH, studied exclusively in cell culture and animal models of gut inflammation — with no published human trial, and honestly, not much of a user-report record either. ## The short version KPV is a **tripeptide** — a chain of just three amino acids (lysine, proline, valine) — that corresponds to the tail end of a natural hormone called alpha-MSH. Researchers became interested in it because it keeps the parent hormone's anti-inflammatory action without the pigment-darkening effect that comes with the full hormone. The direct answer up front: there is no published human clinical trial of KPV. Every finding described below comes from cell cultures or mice, almost all of it in models of inflammatory bowel disease (colitis). That matters for how to read the rest of this page. The mechanism is genuinely interesting and reasonably well worked out at the cell and animal level [6][7][8][9][10], but nothing here has been tested for safety or effect in a human body, and no dose has ever been established in one. This page describes laboratory findings, not a treatment, and recommends no use for any person. ## What it is KPV is the linear tripeptide L-lysyl-L-prolyl-L-valine (Lys-Pro-Val), corresponding to residues 11 through 13 — the C-terminal end — of alpha-melanocyte-stimulating hormone (alpha-MSH). Its molecular formula is C16H30N4O4. Because it is such a small peptide, it is also fragile: it is broken down quickly by peptidases in circulation, which is why so much of the recent published work on KPV is really formulation and delivery research aimed at getting it intact to the tissue where it needs to act. ## How it works KPV retains the anti-inflammatory signaling of its parent hormone, alpha-MSH, without the pigment-darkening (melanogenic) effect. In laboratory models it dampens inflammation primarily by suppressing NF-kB and MAP-kinase signaling pathways and by reducing the production of pro-inflammatory cytokines. A distinctive feature of its biology in the gut is that it does not need a specialized hormone receptor to get into cells: it is taken up directly by intestinal epithelial cells through the di/tripeptide transporter PepT1, a transporter that is itself upregulated in inflamed intestinal tissue — meaning KPV is delivered preferentially to the tissue that is already inflamed [8]. ## What the research shows *Transport mechanism and direct cell effects.* Foundational work established that KPV enters human intestinal epithelial cells (Caco2-BBE and HT29-Cl.19A lines) and immune cells (Jurkat T cells) through the PepT1 transporter, and that nanomolar concentrations of KPV inhibit NF-kB and MAP-kinase inflammatory signaling and reduce pro-inflammatory cytokine secretion. In mice, oral KPV reduced the severity of two different chemically induced colitis models (DSS- and TNBS-induced) [8]. *Colitis models beyond DSS.* A separate study found KPV reduced colonic inflammation in both DSS-induced colitis and a second, immune-cell-transfer model of colitis, with earlier recovery, lower markers of neutrophil activity, and reduced inflammatory infiltrate — and, notably, the effect held up even in mice genetically missing the MC1R receptor that alpha-MSH normally signals through, indicating KPV's anti-inflammatory action does not depend on that receptor [9]. *Delivery and formulation research.* Because free KPV degrades quickly, most of the newer literature focuses on getting it to inflamed tissue intact. A 2024 study built a PepT1-targeted nanoparticle co-assembling KPV with the immunosuppressant FK506, which improved outcomes in both acute and chronic colitis in mice, restored tight-junction proteins in the gut lining, and lowered inflammatory cytokines beyond what either agent achieved alone [6]. An earlier 2017 study delivered KPV orally inside hyaluronic-acid-functionalized nanoparticles embedded in a chitosan/alginate hydrogel, which reduced colitis severity more effectively than non-targeted delivery, cut TNF-alpha production, and sped mucosal healing [7]. *Broader context.* A comprehensive 2008 review situates KPV within a family of melanocortin-derived tripeptides that showed protective effects across a wide range of inflammatory animal models — fever, dermatitis, vasculitis, fibrosis, eye and airway inflammation, arthritis, and organ injury — describing KPV specifically as an anti-inflammatory alternative to full alpha-MSH because it keeps the anti-inflammatory signal without the pigmentary one [10]. ## Reported effects, cautions & safety Here is the blunt part: there is no meaningful body of user-reported experience to draw on for KPV, and this page will not manufacture one. KPV has never been an approved drug, is not sold as a finished consumer product the way copper-peptide skincare or semaglutide are, and does not have the large patient or research-use communities that generate the kind of anecdotal record documented on this site's other three pages. What exists instead is exclusively animal and cell-culture data [6][7][8][9][10] — genuinely useful for understanding mechanism, but not a substitute for the human trial record this compound does not have. *Cautions, drawn from the state of the evidence rather than any specific reported harm:* No published human clinical trials of KPV exist, so human dosing, efficacy, and safety are entirely unestablished — everything about how it behaves in a person is inference from mice, not observation of one. Free KPV is a small, peptidase-labile tripeptide with no validated human pharmacokinetics, which is precisely why so much current research effort goes into formulation rather than dosing. Marketing claims made for KPV around gut health, skin, or general anti-inflammatory use in research-chemical circles run well ahead of an evidence base that is, at every point, mechanistic and preclinical rather than clinical. It is worth noting as well that KPV derives from alpha-MSH but should not be confused with melanocortin agonists marketed for pigmentation or tanning — KPV's entire point in the literature is that it lacks that pigmentary effect. Reported identifier errors (mismatched PMIDs and DOIs) are common in secondary web sources describing KPV; every citation on this page was independently re-verified against PubMed and Crossref rather than copied from an aggregator. KPV is sold by chemical suppliers strictly for laboratory research use and holds no approved drug or dietary-supplement status in any major jurisdiction. ## Where it fits in Research Peptide Fundamentals KPV sits at the far end of this site's evidence-versus-anecdote spectrum, opposite [semaglutide](/semaglutide): almost no evidence of either kind. There is a real, if entirely preclinical, mechanistic case for it [6][7][8][9][10], but there is no human trial and — because it never became a widely distributed consumer product — not much of a genuine community-report record to set alongside it either, unlike [GHK-Cu](/ghk-cu). That absence is itself informative: it shows what a compound looks like before either kind of evidence has caught up with interest in it. See the [comparison page](/compare) for how KPV's evidence profile stacks up against the other three compounds on this desk. ![KPV research illustration — abstract cool scientific motif](/images/kpv.webp) --- This is a research digest that keeps what a study measured separate from what a forum member reported — it is not a clinic, not a supplier, and not medical advice.